PAREXEL International Corporation (NASDAQ:PRXL) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
announced its financial results for the fiscal quarter ended
March 31, 2017. The full text of the press release issued in
connection with the announcement is attached as Exhibit 99.1 to
this Current Report on Form 8-K (the Press Release). The
information in this Item 2.02 (including Exhibit 99.1) shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Press Release dated May 3, 2017.
About PAREXEL International Corporation (NASDAQ:PRXL)
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions. PAREXEL International Corporation (NASDAQ:PRXL) Recent Trading Information
PAREXEL International Corporation (NASDAQ:PRXL) closed its last trading session down -0.83 at 64.54 with 798,898 shares trading hands.